January 17, 2012

Israelis find vitamin D helps against liver diseases

01/17/2012 05:46

Research teams first to discover benefits of treatment against hepatitis C and cirrhosis.

Two Israeli research teams have separately become the first to discover two different benefits from vitamin D against common liver diseases – hepatitis C and cirrhosis.

One involved the mechanism in human cells in the lab, while and the other proved itself on liver tissue in rats. The two discoveries have not yet been tested clinically.

Prof. Ran Tur-Kaspa, from the Rabin Medical Center- Beilinson Campus, and his team worked on hepatitis C, the major factor in chronic liver disease that can lead to cirrhosis. It is also the main cause in the Western world of organ failure requiring a liver transplant and is one of the causes of primary liver cancer.

Antiviral treatment can help in half the cases, but the side effects are serious even if the treatment is effective.

Tur-Kaspa, a liver specialist and researcher who is dean of the Galilee Medical Faculty in Safed, said there is a constant search for medications and other technologies that are more effective and accompanied by fewer side effects.

He and his team investigated ordinary vitamin D, which is already taken by many people as prevention for numerous diseases, to see whether it had any effect on hepatitis C and on liver cells that host it. They discovered, and published in Hepatology, a peer-reviewed medical journal, that vitamin D directly halts the activity of viruses in general and hepatitis C in particular. They also found that a system for actively producing vitamin D is found in liver cells and can activate the immune system and repress the virus.

The research showed without doubt that vitamin D functions in the liver cell, and it causes an increase in naturally produced interferon and repression of the production of the virus, said Dr.
Romy Zemel, who was part of the team. The research proves that integrating the use of interferon and vitamin D boosts the effects synergistically, beyond the effects of each alone.

Interferons are a family of naturally occurring proteins that are made and secreted by immune-system cells. Thus, with the right combination, said the Beilinson researchers, one could destroy the virus. Their discovery was made serendipitously.

Vitamin D is produced as a result of exposure to the sun or taken in the diet or by supplements.

Its classic role, said Tur-Kaspa, is to protect the balance of calcium and phosphorus in the body. Over the years, additional influences such as on the immune system became clear, and at the same time, vitamin D became popular as a number of health benefits were reported.

The Beilinson discovery of the weakening of the hepatitis C virus in the presence of the vitamin opens up a potential treatment for the infections, so one can improve the efficacy of treatment while reducing the dosage of interferon, said Tur- Kaspa.

Meanwhile, the latest issue of Tel Aviv Sourasky Medical Center’s newsletter published an article by Prof. Shimon Reif and colleagues on how vitamin D fights liver cirrhosis, in which liver tissue is replaced by fibrotic scar tissue, usually collagen, leading to the loss of liver function.

Special cells in the liver called hepatic stellate cells (HSCs) collect vitamin D when they are “resting.”

After they are activated, they produce collagen, which leads to fibrosis. Using liver tissue taking from rodents, the Sourasky team treated them with vitamin D and increased the expression of a receptor for the vitamin. This significantly repressed the growth of HSCs, they found.

The same effect was then found in live rats.


ArQule advances drug candidate for liver cancer

Boston Business Journal by Julie M. Donnelly, Reporter
Date: Tuesday, January 17, 2012, 9:12am EST

ArQule Inc. (NASDAQ: ARQL) Said Tuesday that its experimental therapy for the most common form of liver cancer showed positive results in a Phase 2 trial. The Woburn, Mass. biotech said the drug target, tivantinib, when used alone, extended the cancer's time to progression by 56 percent. There are few approved treatments for liver cancer outside of traditional chemotherapy.

The 107 patients in the study either had continued to see their disease progress on currently approved treatments, or could not tolerate them.

The most common primary cancer of the liver, Hepatocellular carcinoma, (HCC) has risen to be the third leading cause of cancer-related death, the company said

“These findings represent the first randomized data reported with a c-Met inhibitor administered as a single agent in HCC,” ArQule chief medical officer Dr. Brian Schwartz said in a statement. “Second-line treatment for HCC remains a challenge, lacking an approved agent. We look forward to presenting complete data from this trial at a peer-reviewed forum later this year, including secondary endpoint, sub-group and biomarker analyses.”

The company reported that side effects of the drug candidate include fatigue neutropenia and anemia. The company said the risk of neutropenia and anemia declined after lowering the dosage of tivantinib.

The company is also studying the potential therapy in two Phase 3 trials to treat non-small cell lung cancer.

The drug candidate is part of a 2008 partnership agreement between ArQule and Japanese drug maker Daiichi Sankyo, Co. Ltd. to co-develop tivantinib in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin Co. Ltd. has exclusive rights for development and commercialization of tivantinib.


Dream of making artificial body parts becoming a reality


by Lachlan Mackinnon, Daily Mirror 17/01/2012

It sounds like a sci-fi movie – doctors growing body parts to cure our ills. But thanks to incredible breakthroughs, bionic repairs for humans are fast becoming a reality.

Experts yesterday revealed they are perfecting “off the shelf” blood vessels, which could revolutionise treatment of heart attacks and strokes.

If the Cambridge University blood vessel team is successful, patients could be spared major operations. The test tube vessels may also treat kidney dialysis patients and repair injuries.

And because the patient’s own skin cells are used, there is less chance of rejection.

Professor Jeremy Pearson, of the British Heart Foundation, said: “This is very advanced. Growing blood vessels means they could be used off the shelf and be put into patients who need bypasses in a leg or heart, which is currently done using their own veins.”

Here are other ways science is giving nature a helping hand...


Experts are working on a cure for blindness - and have taken huge strides towards their goal.

Miikka Terho, 46, from Finland, who suffered an inherited form of blindness called retinitis pigmentosa, was fitted with an experimental chip behind his retina in Germany.

It works by converting light that enters the eye into electrical impulses fed into the optic nerve, restoring some vision.


Bionic ears are transforming the lives of patients. They send sounds from a microphone through a metal coil to electrodes inside the inner ear.

A seven-year-old boy, Troy Probert, who was left deaf after seven meningitis bouts, was able to hear again thanks to computer-activated cochlear implants.


Patients whose windpipes are ravaged by cancer can have new ones grown in the lab. Scientists at University College London crafted a fake windpipe filled with cells taken from a patient’s own bone marrow.

Once fitted, the cells divided and grew to make an organ indistinguishable from a normal one.


Brain “pacemakers” are being developed to treat conditions such as Parkinson’s disease.

Patients with the implants, which send electronic impulses deep inside the brain, reported fewer tremors and stiffness. It involves inserting a wire with electrodes at its tip, which is connected to a small “neurostimulator” unit.


A liquid that can be injected into the face is being developed to help treat disfigured people. Surgeons could use it to rebuild areas damaged by disease or injury.

The liquid, created by Alexander Hillel and his colleagues at Johns Hopkins University, Maryland, US, can be massaged into shape and set using a special light beam.

6. ARM

Amputees could be given a new lease of life with bionic limbs. Livingston-based Touch Bionics’ prostethic arm allowed Patrick Kane, 13, who lost his arm through meningitis, to squash grapes between his fingers.

When he tenses a muscle, tiny pulses of electricity from nerves beneath the electrodes cause the hand to close - and the same process applies for opening his fist.


Paralysed people have been given hope of using their legs again thanks to research using electrodes.

Baseball star Rob Summers, who was told he would be wheelchair-bound after being hit by a speeding car in Portland, Oregon, US, made medical history as the first person paralysed from the chest down to stand and take a step unaided.

Summers’ legs were able to move because of electrical stimulation from a device implanted in his lower spine.


Artificial skin used to heal wounds has been developed by UK researchers.

Writing in the journal Regenerative Medicine, UK-based company Intercytex said it had produced promising results in early trials. The skin is made from fibrin gel, a blood clotting protein, and fibroblast cells found in human skin.


A prosthetic leg that can be programmed for different types of activity and adjusted by Bluetooth has developed by a UK firm.

The limb, which was designed by Otto Bock Healthcare and fitted by ProActive Prosthetics in Elstead, contains a micro-processor which can differentiate between 10 types of activity.

Amputee Matthew Newbury, who is said to be the first person to have the limb fitted, said: “I don’t have to think about every step and therefore I’m not tiring myself out.”


An artificial pancreas has been developed that could be a major advance in the treatment of diabetes.

The metal pancreas, which holds a supply of the hormone insulin kept in place by a gel barrier, could lead to daily insulin injections to control blood sugar levels being unnecessary in the future.

Invented by Professor Joan Taylor at De Montfort University in Leicester, it could move to clinical trials within the next few years.

11. WOMB

Doctors are developing artificial wombs in which embryos can grow outside a woman’s body.

Embryos successfully attached themselves to the walls of these laboratory wombs and began to grow. However, experiments had to be terminated after a few days to comply with in-vitro fertilisation regulations.


Scientists are working on providing replacement muscles for people who suffered serious sporting injuries or damaged limbs in accidents.

They are using gels that expand and contract in response to small electrical currents to create synthetic muscles for replacing heart valves.

Scientists at Nasa’s Jet Propulsion Laboratory in Pasadena are aiming to develop an arm powered by bionic muscles made from these “electroactive polymers” that would be capable of winning an arm-wrestling contest.


Artificial blood created from stem cells could soon be tested on Britons.

The Edinburgh and Bristol university scientists behind the research, which could provide industrial-scale quantities of blood, believe it will transform transfusions by preventing hospital shortages and save thousands of lives on battlefields and at the scene of car crashes.

If they crack the recipe, just one human embryo could theoretically provide all the cells ever needed for Britain’s blood supply.


Scientists have managed to produce a small-scale version of a human liver in the laboratory using stem cells.

The success increases hope new transplant livers could be manufactured, although experts say this is still many years away. UK researchers said it was an “exciting development” but insisted it was not yet certain a fully-functioning liver was possible.


Deadly Dangers from Drugstore Pain Meds a Painful Surprise


Pills, glorious pills - but are they safe? (Image via Wikipedia)

1/17/2012 @ 5:54AM

Could your attempts to cope with common headaches, sore knees or backache be putting you at risk for heart attack, stroke and liver disease? Recent research suggests that both ibuprofen and acetominophen — the two most popular over-the-counter painkillers — carry some potentially and even deadly risks.

Advil and Motrin Linked to Stroke and Heart Attack
Taking ibuprofen and other common NSAIDs (non-steroidal anti-inflammatories) over a long period of time triples the risk of strokes and increases the likelihood of a heart attack, according to this week’s headliner study, published in the British Medical Journal. The new research, conducted at the University of Bern in Switzerland, involved a huge number of subjects; the data were drawn from more than 31 clinical trials involving 116,429 patients. Those who suffered strokes were found to be taking a normal recommended dose (400-600 mg) of ibuprofen three or four times a day.

Meanwhile, the study also found a greatly increased risk of heart attack from all the prescription NSAIDs in the class known as Cox-2 inhibitors. Several years ago, the prescription NSAIDs Vioxx and Bextra were pulled from the market after they were found to put people at risk for heart attack. Another such drug, Celebrex, is still on the market and has also come under attack; a prior study found that people taking Celebrex had twice as many heart attacks as those taking a placebo. The FDA has suggested that people consider alternatives to Celebrex but hasn’t withdrawn its approval. The BMJ study raises the spectre that all the drugs in this class could carry this deadly risk.

Tylenol just as risky – but for your liver
Then there’s last month’s shocker: If you’re regularly taking just a little too much Tylenol (generic name: acetominophen) over the course of the day, you could be permanently damaging your liver and not even know about it. In fact, people who regularly take slightly too much acetominophen over a period of time to relieve pain could be at a higher risk of dying than those who take single overdose of the drug. That’s the message from a study published in the British Journal of Clinical Pharmacology in which researchers tested the blood of people admitted to the hospital and found that the danger of a “staggered overdose,” was much greater than previously thought, often because doctors can’t identify the problem in time to help.

If Tylenol is your go-to painkiller of choice, you’re in good company; acetaminophen is one of the most commonly used drugs in the country, with more than 28 billion doses purchased in the U.S. a year. But since it’s so common, it’s easy to forget it’s an extremely powerful drug; Tylenol overdose is the leading cause of acute liver failure in the U.S., leading to 26,000 hospitalizations and nearly 500 deaths annually, according to the Food and Drug Administration.

Another problem with acetominophen is that’s it’s a standard ingredient in many combination drugs, such as almost all the popular multi-symptom cold remedies, and it’s also in some prescription painkillers like Vicodin. So it’s possible to overdose by mistakenly taking acetominophen in several forms at the same time.

So which painkillers are safe?
Ah, good question. There’s good old aspirin, which hasn’t been associated with serious risks, but also hasn’t been well-studied since it went on the market long before the FDA’s stringent approval proccess was put in place. Aspirin is an NSAID, and as such carries the risk of the standard side effects such as gastrointestinal bleeding and ulcers. However, aspirin has not been linked with heart attack, stroke or liver damage, so that’s something.

Best of all, though, would be to find a treatment that gets at the root cause of your pain, whether it’s headache, back pain, or arthritis. Preventing or eliminating pain through physical therapy, better ergonomic practices, or one of the new biomechanical or neuromuscular therapies. There’s also surgery, of course, but before going that far you might consider one of the new treatments available as an alternative.

At this point, it’s worth considering all your options. Given the risks of these common pain meds, there are many approaches that may be safer in the long run than trying to medicate your pain away.


Enzyme blueprint may improve HIV, hep C treatment


A cartoon of a 'ribbon' presentation of the three dimensional structure of endomannosidase. Red regions are alpha helices, green arrows are beta strands. Credit: Spencer Williams/PNAS

Tuesday, 17 January 2012

by Laura Greenhalgh

Cosmos Online

LONDON: The structure of a unique enzyme in the human body has been identified in a discovery that could lead to treatment against deadly viruses such as HIV and hepatitis C.

Researchers from the University of Melbourne participated in an international collaboration to successfully determine the molecular blueprint of the enzyme endomannosidase, which is involved in synthesising sugar-coated proteins in human cells, and is exploited by viruses to aid their replication.

By describing the structure and activity of the enzyme in unprecedented detail, the new findings published in Proceedings of the National Academy of Sciences pave the way for development of a treatment to prevent viruses from hijacking human cells.

"The implications are quite significant," said Spencer Williams from the University of Melbourne's Bio21 Institute. "Drugs that target the pathway this enzyme is in could be used to stop viruses replicating. And if they can't replicate, then they can't cause disease."

The challenge of HIV, Hepatitis C

Previous efforts to develop treatments have focussed on another group of human enzymes used earlier in the infection process, but these have proved unsuccessful.

"The problem has been that this group of viruses, including HIV, hepatitis C, dengue fever and West Nile virus, are able to bypass the main pathway if inhibited and replicate via a second pathway using endomannosidase. Thus for a treatment to be effective, both pathways need to be blocked," said Williams.

Despite growing knowledge on the location of endomannosidase, scientists remained unable to determine its structure or discover anything about the enzyme's catalytic mechanism. "This endomannosidase bypass pathway has proved a considerable challenge to study," said Gideon Davies, leader of the second research team from the University of York in England.

However, by combining international resources and expertise, the Melbourne and British research teams have for the first time successfully mapped the shape of endomannosidase. In doing so, they also discovered that the enzyme may function via a completely new mechanism.

Unusual endomannosidase

The scientists studied a bacterial version of endomannosidase as a model for the same human enzyme, which they manufactured in sufficient quantities using the bacteria E. coli. They then placed a crystallised form of the enzyme under a powerful X-ray light source and collected the light reflected by individual atoms of the crystal, a state-of-the-art technique known as synchrotron technology.

Using computer software, the researchers then combined the patterns of reflected light to construct a three-dimensional picture of the enzyme. This indicated that endomannosidase contains a barrel-shaped fold in its molecular structure, which houses the enzyme's catalytic centre. The results also indicated the enzyme has some unexpected characteristics.

"It is a surprise in that we expected certain amino acids to be present in specific arrangements, and they were not. As a result we hypothesise that the enzyme is doing its job in an unprecedented new way," said Williams.

The key enzyme

Now the researchers have the molecular blueprint for the enzyme, they can begin to develop drug treatments. "These findings have revealed how we can block the bypass route, stopping the viruses from hijacking human enzymes," said Williams.

This could have significant consequences for the 180 million people infected by viruses like HIV and hepatitis worldwide, and ultimately could benefit an even greater number of people. "We hope that the work will lead beyond viruses and will point the way towards similar treatments for other diseases, including cancer," said Davies.

Commenting on the findings, Keith Stubbs from the University of Western Australia in Perth said, "This research addresses a key enzyme in N-glycan processing that has not been rigorously studied from a structural and biochemical perspective. It now opens the door for further study into how this enzyme is involved in the processing pathway from both a biotechnological and therapeutic perspective."

Williams cautioned that successful treatment may be some way off, but that their latest findings mark a significant breakthrough in this area. "Science moves slowly and in small steps," he said, "but now that we have inhibitors of both pathways we will see if dual inhibition can assist in curing a cell of hepatitis C infection. If this is the case then we will have 'proof-of-concept' that our strategy can be developed further."


Kidney failure risk higher for liver transplant patients following allocation policy change

Pratima Sharma, M.D., M.S., is an assistant professor in the Department of Internal Medicine

January 16, 2012


Media Contacts : Justin Harris: juaha@umich.edu 734-764-2220

U-M researchers identify modifiable risk factors that could limit the incidence of post-transplant end-stage renal disease

Research from the University of Michigan Health System shows the risk for kidney failure among liver transplant recipients is higher following the implementation of Model of End Stage Liver Disease (MELD), a policy change in 2002 that altered how liver transplant allocation is decided.

The study, led by Pratima Sharma, M.D., M.S., an assistant professor in the Department of Internal Medicine, examined the effect of MELD score-based allocation on post-liver transplant kidney failure. MELD, which was introduced in 2002, is a scoring system that evaluates liver disease severity and has since become the basis for deciding which patients receive liver transplants.

The researchers found that the risk of developing post-transplant kidney failure among liver transplant recipients has increased by 15 percent in the MELD era compared to pre-MELD era. The findings were featured in the November 2011 issue of the American Journal of Transplantation.

“We’re not aware of any prior study that has evaluated the impact of MELD-based liver allocation on the risk of new-onset post-transplant kidney failure,” says Sharma. “These findings identify risk factors that could help prevent new-onset end stage renal failure in liver-transplant recipients.”

The researchers previously found that the MELD score excessively weighs the presence of serum creatinine in deciding which patients receive liver transplants. Higher levels of serum creatinine are a sign of renal dysfunction.

When MELD was implemented, more patients with pre-transplant kidney dysfunction began receiving liver transplants. The incidence of simultaneous liver and kidney transplant has also increased significantly in the MELD era.
Researchers say that along with the increasing incidence of post-transplant kidney failure, chronic kidney disease could also be on the rise, affecting health care costs in the future.

“The higher incidence of post-transplant kidney failure may represent the tip of the iceberg,” Sharma says. “Patients with chronic kidney disease could develop kidney failure in the future, which may add to already skyrocketing healthcare costs in terms of additional dialysis cases and increased hospitalization.”

The findings also highlight several modifiable risk factors that could be addressed before, during or after liver transplant and help prevent post-transplant kidney failure.

The researchers found that along with African American race, hepatitis C, pre-liver-transplant diabetes, higher creatinine, lower albumin, low bilirubin and high sodium were significant predictors of post-liver transplant kidney failure.

“Modification of some of these risks that would improve renal function may help prevent or delay post-liver transplant kidney failure,” Sharma says.

# # #

Additional authors: From U-M: D. E. Schaubel, A. O. Ojo and R. M. Merion; From Arbor Research Collaborative for Health: M. K. Guidinger, N. P. Goodrich

Citation: American Journal of Transplantation, DOI: 10.1111/j.1600-6143.2011.03703.x; Nov. 1, 2011. “Impact of MELD-Based Allocation on End-Stage Renal Disease After Liver Transplantation.”

Disclosures: None

Funding: The research was supported by the American Society of Transplantation, the National Institutes of Health and the Scientific Registry of Transplant Recipients.


Researchers Discover Means for Blocking Hepatitis C Infection

By Adam Daley

Researchers in Canada have discovered a new approach to blocking infection from the hepatitis C virus in the liver that could lead to new therapies.

HCV requires fat to replicate, and a team of scientists at the University of British Columbia have developed an inhibitor that decreases the size of host fat droplets in liver cells and stops the virus from multiplying and infecting other cells.

"Our approach would essentially block the lifecycle of the virus so that it cannot spread and cause further damage to the liver," said Fran├žois Jean, Associate Professor in the Department of Microbiology and Immunology and Scientific Director of the Facility for Infectious Disease and Epidemic Research (FINDER) at UBC.

The research is published in the journal PLoS Pathogens

Read the full article here …


A Recently Published Study Investigating Anti-Oxidants For Diabetics Suggests A Nutrient, Alpha Lipoic, Resulted in General Systemic Improvement, Including Liver Health


A recently published study, in the European Journal of Nutrition, investigating the effects and benefits of Alpha Lipoic and diabetic disturbance in the red blood cells of the animals, revealed Alpha Lipoic, a vital biological co-enzyme, also found in food, increased antioxidant activities in the red blood cells, elevated the glutathione (a biological anti-oxidant), lowered Glycation, reduced triglycerides, reduced hyperglycemia and reduced two enzymes, ALT and AST, which are normally elevated in human diabetes. Expanding on this study, Nutri-Med Logic Corp states that another recently published report, summarizing the results of the studies of last 10 years on R-Alpha Lipoic, concluded that R-Alpha Lipoic is the most effective anti-oxidant in Diabetic Neuropathy, in humans, as well

Miami, FL (PRWEB) January 16, 2012

Nutri-Med Logic Corp: Over the last 40 years, many studies have reported the benefits of R-Alpha Lipoic in Diabetes. A search of all published studies in PubMed reveals that this recently published study, in the European Journal of Nutrition, is the first to report a reduced level of ALT (Alanine Aminotransferase), an indicator of liver injury, as well as reduced levels of AST (aspartate aminotransferases ), also a marker of liver health but also found in heart (cardiac muscle), kidneys, brain and red blood cells, in the study of diabetes and Alpha Lipoic.

According to the American Diabetes Association, chronic or even mild elevations of ALT and AST is frequently found in type 2 diabetic patients and/or generally conveys an underlying insulin resistance. The concentration of intracellular hepatic (liver) enzymes that have leaked into the circulation could be a predicator of liver injury. (1)

High AST levels, also, generally manifest liver damage or muscle damage or both, which arises from metabolic disorders, as well.

The reduced form of R-Alpha Lipoic Acid is a vital and biological co-enzymes, produced by the cells in the metabolism of glucose (production of energy). R-Alpha Lipoic is found in variety of food but its concentration does not increase significantly form food but only from its dietary supplementation.

In Germany, R-Alpha Lipoic (also known as R-Lipoic Acid) has been used, for more four decades, as a co-therapy in the treatment of Diabetic Poly-Neuropathy. As the matter of fact, a newly published report on clinical trials of last 10 years, relating to the benefits of R-Alpha Lipoic and the various claims made about it, found Diabetic Polyneuropathy receiving the clearest benefit from R-Alpha Lipoic. (2)

In Japan, Alpha Lipoic Acid was previously sold only as a medicine. In June 2004, the Ministry of Health, Labor, and Welfare of Japan reclassified Alpha Lipoic Acid as a nutrient.

Interestingly, the first human clinical studies in the United States was carried out in late 70's by Dr. Fredrick C. Bartter and Dr. Burton M. Berkson, two associates of the National Institutes of Health for the treatment of chronic liver damage, with about 95% improvement (75 out of 79).

Dr. Burkson, subsequently, received a special license from FDA for the intravenous application of Alpha Lipoic Acid and has been the FDA principal Investigator for intravenous application of Alpha Lipoic Acid for the last 23 years.

In 1996, Professor Lester Packer a senior anti-oxidant researcher and scientist at the University of California (Berkley) declared R-Alpha Lipoic as a universal antioxidant, since it dissolves in water and fat, thus, capable of reaching the entire body.

In the United States, R-Alpha Lipoic Acid is dietary supplement and its application as nutrient should not be confused with its IV application.

In conclusion, Nutri-Med Logic Corp agrees with this recent study and adds that R-Alpha Lipoic is also an effective dietary supplement for Diabetes Neuropathy. Additionally, when taking the results of this study, improvement of ALT and AST in liver of diabetic animals, together with the reversal of liver disease, by Dr. Burkson, R-Alpha Lipoic may have extended its benefits beyond its sole association with diabetes and might offer benefits as a general liver dietary supplement, as well.

Nutri-Med Logic Corp. is a producer of dietary supplements, including a Pharmaceutical Grade R-Alpha Lipoic Acid, the dietary supplement of choice for the Diabetics, in Germany for more than 40 years.

Nutri-Med Logic Corp is also producer of a Natural, Balanced, Deodorized and Concentrated Omega-3, which is also a Pharmaceutical Grade Omega-3;

Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy and the recommended dietarty supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for about 50 years.

Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements above or below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.

1. Clinical Diabetes July 2005 vol. 23 no. 3 115-119
2. Front Pharmacol. 2011;2:69. Epub 2011 Nov 17.